Artivion, Inc. (AORT)

NYQ – Real vaqt narxi. Valyuta: USD

23.10

-0.71 (-2.98%)

Yopilishda: May 12, 2026, 4:00 PM EDT

23.75

+0.65 (2.81%)

Bozordan keyin: May 12, 2026, 7:59 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Artivion, Inc. (AORT)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Artivion, Inc. (AORT)

Shareholder Alert: Ademi LLP Investigates Claims of Securities Fraud against Artivion, Inc.

Artivion, Inc. (AORT) Q1 2026 Earnings Call Transcript

Artivion Q1 Earnings Call Highlights

Artivion (AORT) Q1 Earnings and Revenues Surpass Estimates

Artivion Reports First Quarter 2026 Financial Results and Announces Exercise of Option to Acquire Endospan

Artivion Announces Release Date and Teleconference Call Details for First Quarter 2026 Financial Results

Artivion Secures FDA Approval for NEXUS Aortic Arch System

Videolar

No Data

Press-relizlar

Shareholder Alert: Ademi LLP Investigates Claims of Securities Fraud against Artivion, Inc.

Artivion Reports First Quarter 2026 Financial Results and Announces Exercise of Option to Acquire Endospan

Artivion Announces U.S. FDA Approval of the NEXUS® Aortic Arch System

Artivion to Participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference

Search stocks

Artivion, Inc. (AORT)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Artivion, Inc. (AORT)

Shareholder Alert: Ademi LLP Investigates Claims of Securities Fraud against Artivion, Inc.

Artivion, Inc. (AORT) Q1 2026 Earnings Call Transcript

Artivion Q1 Earnings Call Highlights

Artivion (AORT) Q1 Earnings and Revenues Surpass Estimates

Artivion Reports First Quarter 2026 Financial Results and Announces Exercise of Option to Acquire Endospan

Artivion Announces Release Date and Teleconference Call Details for First Quarter 2026 Financial Results

Artivion Secures FDA Approval for NEXUS Aortic Arch System

Videolar

No Data

Press-relizlar

Shareholder Alert: Ademi LLP Investigates Claims of Securities Fraud against Artivion, Inc.

Artivion Reports First Quarter 2026 Financial Results and Announces Exercise of Option to Acquire Endospan

Artivion Announces U.S. FDA Approval of the NEXUS® Aortic Arch System

Artivion to Participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference